Skip to main content

Liver Stem Cells Discovered in Mice

Scientists successfully identified and grew a renewable population of liver stem cells for the first time, a new study reported. Tissues derived from these stem cells slightly boosted liver function when implanted into mice with a liver disorder. The findings could eventually lead to approaches that help rejuvenate damaged livers in people.
Confocal microscope image showing mass of cells with green and red areas.
A single cell was coaxed to mature into liver cells that produce common liver proteins (green and red). Image courtesy of Huch et al., Nature.
The liver is a large, versatile organ that has many jobs, including cleansing blood and digesting food. The liver also has a unique ability to quickly regenerate and regain its original size if partially removed by surgery. Scientists have long known that stem cells that have the potential to create more liver cells must exist in the adult liver. But until now, no one had found a way to detect and cultivate liver stem cells.
An international team led by Dr. Hans Clevers at the Hubrecht Institute, The Netherlands, sought to identify and grow mouse liver stem cells. Their work was funded in part by the European Union and NIH’s National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Results were described in Nature on February 14, 2013.
In earlier studies, Clevers and colleagues discovered that a protein called Lgr5 is found on the surface of rapidly dividing stem cells in the intestine, stomach and hair follicles. In all of these tissues, growth is prompted by signaling molecules known as Wnt proteins, which regulate expression ofLgr5 and many other genes. Wnt signaling is known to play a role in tissue regeneration, embryo development and cancer.
To see if Lgr5 might also be a marker for liver stem cells, the scientists studied genetically engineered mice in which Lgr5 genes were tagged by “reporter” genes. The researchers found that the gene was not activated in healthy mouse livers. But in injured livers, small Lgr5-positive cells appeared near the bile ducts—a location where resting liver stem cells were thought to reside. The cells also showed signs of Wnt signaling.
The researchers traced Lgr5-positive liver cells in mice after liver injury. Within a week, they detected small, fast-growing Lgr5 offspring cells, which later evolved into bile duct cells and liver cells.
To grow Lgr5-positive liver cells, the researchers used a 3-D culture system they’d previously developed for growing stem cells into tiny clumps, or “organoids.” Some of the cultures were propagated from a single Lgr5-positive cell. All were grown in a special medium that enhances Wnt signaling.
The team was able to grow and propagate the resulting liver organoids for several months. In culture, the organoids could be coaxed into generating functional liver and bile duct cells. When the organoids were injected into mutant mice with a deadly liver enzyme deficiency, patches of enzyme-producing liver cells appeared in the livers of 5 of the 15 treated mice. Mice with successful organoid transplants survived significantly longer than untreated enzyme-deficient mice.
“This study raises the hope that the human equivalent of these mouse liver stem cells can be grown in a similar way and efficiently converted into functional liver cells,” says coauthor Dr. Markus Grompe of the Oregon Health and Science University School of Medicine. Going forward, the researchers plan to test other growth factors and conditions to improve the efficiency of the procedure.

Comments

Popular posts from this blog

Monoclonal Antibody Targets, Kills Leukemia Cells

Monoclonal Antibody Targets, Kills Leukemia Cells  Researchers at the University of California, San Diego Moores Cancer Center have identified a humanized monoclonal antibody that targets and directly kills chronic lymphocytic leukemia (CLL) cells The findings, published in the online Early Edition of the Proceedings of the National Academy of Sciences on March 25, 2013 represent a potential new therapy for treating at least some patients with CLL, the most common type of blood cancer in the United States. CLL cells express high levels of a cell-surface glycoprotein receptor called CD44. Principal investigator Thomas Kipps, MD, PhD, Evelyn and Edwin Tasch Chair in Cancer Research, and colleagues identified a monoclonal antibody called RG7356 that specifically targeted CD44 and was directly toxic to cancer cells, but had little effect on normal B cells. Moreover, they found RG7356 induced CLL cells that expressed the protein ZAP-70 to undergo apoptosis or programmed cell death.

Stem Cell Treatment May Become Option to Treat Nonhealing Bone Fractures

Stem Cell Treatment May Become Option to Treat Non healing Bone Fractures Stem cell therapy enriched with a bone-regenerating hormone, insulin-like growth factor-I (IGF-I), can help mend broken bones in fractures that are not healing normally, a new animal study finds. The results are being presented at The Endocrine Society's 93rd Annual Meeting in Boston. A deficiency of fracture healing is a common problem affecting an estimated 600,000 people annually in North America, according to the principal investigator, Anna Spagnoli, MD, associate professor of pediatrics and biomedical engineering at the University of North Carolina at Chapel Hill. "This problem is even more serious," Spagnoli said, "in children with osteogenesis imperfecta, or brittle bone disease, and in elderly adults with osteoporosis, because their fragile bones can easily and repeatedly break, and bone graft surgical treatment is often not successful or feasible" Fractures that do not hea

Erythropoietin as a Retinal Angiogenic Factor in Proliferative Diabetic Retinopathy

Although vascular endothelial growth factor (VEGF) is a primary mediator of retinal angiogenesis, VEGF inhibition alone is insufficient to prevent retinal neovascularization. Hence, it is postulated that there are other potent ischemia-induced angiogenic factors. Erythropoietin possesses angiogenic activity, but its potential role in ocular angiogenesis is not established. METHODS We measured both erythropoietin and VEGF levels in the vitreous fluid of 144 patients with the use of radioimmunoassay and enzyme-linked immunosorbent assay. Vitreous proliferative potential was measured according to the growth of retinal endothelial cells in vitro and with soluble erythropoietin receptor. In addition, a murine model of ischemia-induced retinal neovascularization was used to evaluate erythropoietin expression and regulation in vivo. RESULTS The median vitreous erythropoietin level in 73 patients with proliferative diabetic retinopathy was significantly higher than that in 71 patients with